You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯港股聚焦(06.01)︱中國恆大5月合約銷售額達638.6億元;中國燃氣與北京北燃實業集團訂立戰略合作協議
格隆匯 06-01 23:10

【業績預吿】

永發置業(00287.HK)全年預虧200萬至600萬港元

阿爾法企業(00948.HK)預期年度虧損大幅減少

【運營數據】

中國恆大(03333.HK)5月合約銷售額達638.6億元

金輝控股(09993.HK):5月合約銷售106.6億元 同比增長38.3%

佳兆業集團(01638.HK):5月合約銷售118億元 按年增加約30.4%

當代置業(01107.HK)5月份合約銷售額41.49億元 同比增長23.87%

合景泰富集團(01813.HK)5月預售額為113.01億元 同比增加23.5%

【增減持】

都市麗人(02298.HK)獲主要股東及主席鄭耀南增持305.4萬股

建業地產(00832.HK)獲控股股東繼續增持200萬股

華記環球集團(02296.HK)獲主席兼控股股東盧卓明購入378.4萬股公司普通股及120萬份認股權證

昊海生物科技(06826.HK):持股5.26%股東樓國樑擬減持不超216.5萬股

阿爾法企業(00948.HK)預期年度虧損大幅減少

併購出售】

廖創興企業(00194.HK)擬24.8億泰銖收購泰國蘇梅島東北物業

國銀租賃(01606.HK)擬1.298億美元購買六艘船舶

福晟國際(00627.HK)擬出售香港多處物業

【增發供股】

信陽毛尖(00362.HK)擬先舊後新配股 淨籌2920萬港元用作營運

【投資運營】

第一服務控股(02107.HK)附屬與蜻蜓FM達成戰略合作 共同探索音頻媒體增值服務

中國生物製藥(01177.HK):新型利尿藥物“託伐普坦片”獲藥品註冊證書

中國燃氣(00384.HK)與北京北燃實業集團訂立戰略合作協議

Platt Nera(01949.HK)附屬擬在泰國成立合營公司 以投資及開發現金存款機項目

海普瑞(09989.HK):全人源單克隆抗體藥物(AR-301)III期藥品臨牀試驗補充申請獲國家藥監局批准

再鼎醫藥-SB(09688.HK)擬攜手Mirati Therapeutics在大中華區開發和商業化Adagrasib

永義國際(01218.HK)在拍賣中成功中標漆鹹道北大廈

亞博科技(08279.HK)贏得彩票終端機採購招標項目 將向多省供應彩票終端機

藍河控股(00498.HK)獲得保華建業約10%股東投票權的轉讓

【回購註銷】

羚鋭製藥(600285.SH)截至5月末累計斥資1.55億元回購2.85%股份

天鴿互動(01980.HK)6月1日耗資294.3萬港元回購206.1萬股

爪哇控股(00251.HK)6月1日耗資2553.1萬港元回購310萬股

海爾智家(06690.HK)6月1日耗資3551.50萬港元回購111.16萬股H股

歡喜傳媒(01003.HK)6月1日耗資221.56萬港元回購115萬股

第一太平(00142.HK)6月1日耗資273.8萬港元回購99.6萬股

【股權激勵】

晶門半導體(02878.HK)授出540萬份購股權

利華控股集團(01346.HK)授出640萬份購股權

光控精技(03302.HK)6月1日授出1850萬份購股權

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account